LUNA 18
Alternative Names: LUNA-18; LUNA18 CapsuleLatest Information Update: 02 Oct 2021
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Sep 2021 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (PO) (NCT05012618)
- 08 Sep 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA (PO) (NCT05012618)
- 23 Aug 2021 Chugai Pharmaceutical plans a phase I trial in Solid tumours (Combination therapy, Monotherapy, Metastatic disease, Late-stage disease, Recurrent) (PO, Capsule) in August 2021 (NCT05012618)